Human genome-based regulatory elements, experimentally validated and ready for evaluation and licensing for your cell or gene therapy program.
For programs where speed matters, or where a well-characterized element already fits, a bespoke design may not be needed. Annogen offers a growing portfolio of off-the-shelf promoters for evaluation and licensing. Each has been developed with the SuRE™ platform and validated in relevant cell systems, including in vivo. They are human genome-based, avoiding the viral or synthetic exogenous sequences used by many catalog promoters, which improves expression characteristics and stability and eases regulatory approval.
Constitutive promoters designed be active in any cell type.
Novel promoters demonstrating skeletal muscle specificity in in vivo mouse experiments
Improvements relative to the hAAT promoter shown in vivo in mice.
In development
Inflammation inducible promoter designed in neurons and validated in mouse MS models
Promoters designed to be active in both neurons and glia while achieving higher expression than Syn1 in neurons.
T-cell specific promoters reaching 10-30% of EF1a while showing very low off-target expression. Data in primary human cells.
Enhancer additions to the troponin promoter to increase expression level while maintaining specificity. In vivo mouse data available.
Microglia specific promoter with expression levels similar to PGK and low off-target expression, including in macrophages.
Promoters activated upon T-cell activation to, for example, drive expression of armor. Data in primary human cells.
In development.
You can test our promoters before committing to anything. Annogen offers a standard evaluation period of 6 months, during which selected promoters can be provided in a standard backbone or cloned into your vector, either by Annogen or a third party of choice. The licensing option, under predefined terms, remains available until the end of the evaluation period and may be exercised at the evaluator’s sole discretion. In some cases, exclusivity is an option as well.
We imagine there could be some questions you want to ask us. Discover the most frequently asked questions about this subject right here.
We spike well-known promoters into each screen as references, so every candidate is reported relative to elements you already know. This lets you judge our promoters against your current benchmark directly rather than in the abstract.
Specificity comes from comparison, so we counter-screen candidates against the off-target cell types you want to avoid, not only the target cell. An element is only called specific when it is active where you want it and quiet where you do not want expression.
Yes, you can evaluate an off-the-shelf promoter under an evaluation agreement before committing to a full license, so you can confirm it performs in your system first.
Yes. You do not have to hand over your proprietary vector backbone to us. We typically work through a third-party cloning service, so neither party has to share sequences they want to keep confidential.
Yes, we work from standard evaluation and material-transfer templates and can send them early so your legal team reviews in parallel. Evaluation periods are typically 6 months and, unless agreed otherwise, run from when you receive the material rather than from signing, so cloning or vector production does not eat into your time. We set the exact window in the agreement.
Let’s start with your goals.
Share your challenges, questions or ambitions. We will help you explore how our off-the-shelf promoters can support the decisions ahead.
We use cookies to personalize content, provide social media features, and analyze our traffic. We also share information about your use of our site with our analytics partners. You can change your preferences at any time. For more information, please see our Privacy Policy and Cookie Policy.